GMED Valuation

Globus Medical Inc

Add to Watchlist

Advanced Chart

53.450

-0.59(-1.092%)1D

Overview
Forecast
Valuation
Earnings

GMED Relative Valuation

GMED's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, GMED is overvalued; if below, it's undervalued.

Historical Valuation

Globus Medical Inc (GMED) is now in the Undervalued zone, suggesting that its current forward PE ratio of 16.53 is considered Undervalued compared with the five-year average of 27.25. The fair price of Globus Medical Inc (GMED) is between 71.82 to 104.72 according to relative valuation methord. Compared to the current price of 54.04 USD , Globus Medical Inc is Undervalued By 24.75%.

Relative Value

Fair Zone

71.82-104.72

Current Price：54.04

24.75%

Undervalued

16.53

Trailing

Forward

8.28

EV/EBITDA

Globus Medical Inc. (GMED) has a current EV/EBITDA of 8.28. The 5-year average EV/EBITDA is 13.91. The thresholds are as follows: Strongly Undervalued below 6.50, Undervalued between 6.50 and 10.20, Fairly Valued between 17.61 and 10.20, Overvalued between 17.61 and 21.31, and Strongly Overvalued above 21.31. The current Forward EV/EBITDA of 8.28 falls within the Undervalued range.

15.17

EV/EBIT

Globus Medical Inc. (GMED) has a current EV/EBIT of 15.17. The 5-year average EV/EBIT is 21.31. The thresholds are as follows: Strongly Undervalued below 11.30, Undervalued between 11.30 and 16.31, Fairly Valued between 26.32 and 16.31, Overvalued between 26.32 and 31.32, and Strongly Overvalued above 31.32. The current Forward EV/EBIT of 15.17 falls within the Undervalued range.

2.47

Globus Medical Inc. (GMED) has a current PS of 2.47. The 5-year average PS is 5.11. The thresholds are as follows: Strongly Undervalued below 1.56, Undervalued between 1.56 and 3.34, Fairly Valued between 6.88 and 3.34, Overvalued between 6.88 and 8.66, and Strongly Overvalued above 8.66. The current Forward PS of 2.47 falls within the Undervalued range.

0.00

P/OCF

Globus Medical Inc. (GMED) has a current P/OCF of 0.00. The 5-year average P/OCF is 16.94. The thresholds are as follows: Strongly Undervalued below -9.92, Undervalued between -9.92 and 3.51, Fairly Valued between 30.37 and 3.51, Overvalued between 30.37 and 43.80, and Strongly Overvalued above 43.80. The current Forward P/OCF of 0.00 falls within the Undervalued range.

15.71

P/FCF

Globus Medical Inc. (GMED) has a current P/FCF of 15.71. The 5-year average P/FCF is 38.71. The thresholds are as follows: Strongly Undervalued below -48.39, Undervalued between -48.39 and -4.84, Fairly Valued between 82.27 and -4.84, Overvalued between 82.27 and 125.82, and Strongly Overvalued above 125.82. The current Forward P/FCF of 15.71 falls within the Historic Trend Line -Fairly Valued range.

Globus Medical Inc (GMED) has a current Price-to-Book (P/B) ratio of 1.79. Compared to its 3-year average P/B ratio of 2.65 , the current P/B ratio is approximately -32.36% higher. Relative to its 5-year average P/B ratio of 3.27, the current P/B ratio is about -45.24% higher. Globus Medical Inc (GMED) has a Forward Free Cash Flow (FCF) yield of approximately 7.11%. Compared to its 3-year average FCF yield of 2.48%, the current FCF yield is approximately 186.36% lower. Relative to its 5-year average FCF yield of 2.51% , the current FCF yield is about 183.23% lower.

1.79

P/B

Median3y

2.65

Median5y

3.27

7.14

FCF Yield

Median3y

2.48

Median5y

2.51

Competitors Valuation Multiple

The average P/S ratio for GMED's competitors is 2.51, providing a benchmark for relative valuation. Globus Medical Inc Corp (GMED) exhibits a P/S ratio of 2.47, which is -1.44% above the industry average. Given its robust revenue growth of -1.41%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Bio Rad Laboratories Inc

Performance Decomposition

Market capitalization of GMED decreased by 24.90% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 3.22 to 40.45.

The secondary factor is the Revenue Growth, contributed -1.41%to the performance.

Overall, the performance of GMED in the past 1 year is driven by P/E Change. Which is more unsustainable.

-1.41%

606.67M → 598.12M

Revenue Growth

-1178.63%

-1.17 → 12.62

Margin Expansion

1155.14%

3.22 → 40.45

P/E Change

-24.90%